Venus Remedies

Venus Remedies EBIT

The EBIT of Venus Remedies (VENUSREM.NS) as of Nov 22, 2026 is 1.22 B INR. In the previous year, EBIT was 410.30 M INR — a change of 196.39% (higher).

EBIT

1.22 BINR

YoY

196.39%

Last updated:

In 2026, Venus Remedies's EBIT was 1.22 B INR, a 196.39% increase from the 410.30 M INR EBIT recorded in the previous year.

The Venus Remedies EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2020
111.79 M INR
Jan 1, 2021
108.79 M INR
Jan 1, 2022
280.97 M INR
Jan 1, 2023
273.20 M INR
Jan 1, 2024
331.57 M INR
Jan 1, 2025
410.30 M INR
Jan 1, 2026
1.22 B INR
Jan 1, 2027 (e)
0.00 INR
The Venus Remedies EBIT history
YEAREBITYoY
est0.00INR-100.00%
1.22 BINR+196.39%
410.30 MINR+23.74%
331.57 MINR+21.37%
273.20 MINR-2.77%
280.97 MINR+158.26%
108.79 MINR-2.68%
111.79 MINR-1,068.45%
-11.54 MINR-118.34%
62.94 MINR+49.67%
42.05 MINR+19.90%
35.07 MINR+32.44%
26.48 MINR-96.17%
690.79 MINR+10.22%
626.72 MINR-20.00%
783.43 MINR+9.57%
714.97 MINR+18.28%
604.49 MINR+5.99%
570.31 MINR+18.56%
481.02 MINR+46.38%
328.61 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Venus Remedies Revenue

Venus Remedies Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
3.37 B INR
111.79 M INR
-99.99 M INR
Jan 1, 2021
5.48 B INR
108.79 M INR
617.65 M INR
Jan 1, 2022
5.99 B INR
280.97 M INR
407.24 M INR
Jan 1, 2023
5.56 B INR
273.20 M INR
265.70 M INR
Jan 1, 2024
5.91 B INR
331.57 M INR
284.91 M INR
Jan 1, 2025
6.48 B INR
410.30 M INR
453.20 M INR
Jan 1, 2026
7.70 B INR
1.22 B INR
1.03 B INR
Jan 1, 2027 (e)
8.53 B INR
0.00 INR
549.47 M INR

Venus Remedies Margins

Venus Remedies stock margins

The Venus Remedies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Venus Remedies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Venus Remedies.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
45.08 %
3.32 %
-2.97 %
Jan 1, 2021
19.57 %
1.98 %
11.27 %
Jan 1, 2022
33.48 %
4.69 %
6.80 %
Jan 1, 2023
40.42 %
4.92 %
4.78 %
Jan 1, 2024
36.90 %
5.61 %
4.82 %
Jan 1, 2025
25.66 %
6.33 %
7.00 %
Jan 1, 2026
34.82 %
15.80 %
13.35 %
Jan 1, 2027 (e)
34.82 %
0.00 %
6.44 %

Venus Remedies Stock analysis

What does Venus Remedies do? Venus Remedies Ltd. manufactures and trades pharmaceutical products, focusing on injectables, tablets, and topical preparations for therapeutic segments including anti-infective, oncology, skin and wound care, and pain management. The company's brands such as Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful, and Nervolize cater to critical care and super specialty markets. Its product portfolio addresses antimicrobial resistance (AMR), oncology, neurology, anticoagulants, and herbal solutions, serving medicine, surgery, neuro, and orthopedics. The firm operates in the Pharmaceutical Formulation segment with three manufacturing facilities. The company sells its pharmaceutical products to healthcare providers and institutions globally, targeting critical care and super specialty segments. Brands like Potentox and Vancoplus Combi are positioned for antimicrobial resistance (AMR) solutions, while Neurotol and Trois serve neurology and orthopedics. Supime and Zydotum focus on pain management and skin care, and Septiloc and Mucomelt address anticoagulants and wound care. Venus Remedies' formulations include injectables, tablets, and topical preparations for diverse therapeutic needs. Venus Remedies Ltd. generates revenue through the sale of its branded pharmaceutical products, including injectables, tablets, and topical preparations. The company's product lines target specific therapy areas such as AMR, oncology, skin and wound care, and pain management, with brands like Ventaful and Nervolize supporting neurology and anticoagulant markets. The firm's global reach in injectable manufacturing and focus on super specialty segments drive its market positioning within the Pharmaceutical Formulation segment. Venus Remedies is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Venus Remedies's EBIT

Venus Remedies's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Venus Remedies's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Venus Remedies's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Venus Remedies’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Venus Remedies stock

EBIT of Venus Remedies is 1.22 B INR in 2026.

EBIT of Venus Remedies changed from 410.30 M INR to 1.22 B INR, representing a 196.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Venus Remedies since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Venus Remedies historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Venus Remedies

All Key Metrics — Venus Remedies